TY - JOUR
T1 - Current salvage therapies in Hodgkin lymphoma
AU - Chohan, Karan
AU - Ansell, Stephen M.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Hodgkin lymphoma is a B-cell malignancy with approximately 85–95% complete remission rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10–30% of patients after treatment. Salvage therapy conventionally relies upon cytotoxic chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. A considerable number of patients experience relapse after transplantation, and further salvage management has included the use of allogeneic transplantation and radiotherapy. In the past decade, novel therapies including, brentuximab vedotin, PD-1 inhibitors, and the incorporation of PET-imaging into management have changed the paradigm of relapsed/refractory disease care. Novel therapies have been investigated in both single and combination regimens with other novel therapies and traditional chemotherapies. There is promising early work into the utility of CD30.CAR-T cell therapy, AFM13, camidanlumab tesirine, novel PD-1 inhibitors, and JAK1/JAK2 inhibition in management. Herein, we will review current salvage therapies in Hodgkin lymphoma and future directions in relapsed/refractory disease management.
AB - Hodgkin lymphoma is a B-cell malignancy with approximately 85–95% complete remission rate following frontline therapy; however, relapsed/refractory disease occurs in roughly 10–30% of patients after treatment. Salvage therapy conventionally relies upon cytotoxic chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. A considerable number of patients experience relapse after transplantation, and further salvage management has included the use of allogeneic transplantation and radiotherapy. In the past decade, novel therapies including, brentuximab vedotin, PD-1 inhibitors, and the incorporation of PET-imaging into management have changed the paradigm of relapsed/refractory disease care. Novel therapies have been investigated in both single and combination regimens with other novel therapies and traditional chemotherapies. There is promising early work into the utility of CD30.CAR-T cell therapy, AFM13, camidanlumab tesirine, novel PD-1 inhibitors, and JAK1/JAK2 inhibition in management. Herein, we will review current salvage therapies in Hodgkin lymphoma and future directions in relapsed/refractory disease management.
KW - Hodgkin lymphoma
KW - Salvage
KW - relapsed/refractory
UR - http://www.scopus.com/inward/record.url?scp=85122848926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85122848926&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.2024819
DO - 10.1080/10428194.2021.2024819
M3 - Review article
C2 - 35037568
AN - SCOPUS:85122848926
SN - 1042-8194
VL - 63
SP - 1267
EP - 1280
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -